At present, we are building a rich clinical stage product pipeline containing a variety of autologous and allogeneic candidate products, which is expected to be significantly different from the current car-t cell therapy in the industry. By establishing partnerships with clinicians and key opinion leaders in China, the United States and Europe, we strive to develop more candidate products leading the development direction of the industry. At the same time, we cooperate with top hospitals in China, Verify and improve the safety and effectiveness of innovative candidate products in the trial (IIT) initiated by researchers according to international standards, so as to provide necessary data support for registration application and clinical development worldwide in the future. All our existing candidate products come from internal research and development. See the following chart for the latest progress of candidate products:

In addition to the current leading products, we also have a wide range of earlier candidate product combinations targeting different tumor indications, including ovarian cancer, breast cancer, peripheral T cell lymphoma (PTCL, NHL subtype) and T lymphoblastic lymphoma (T-LBL).